Companies · Biotechnology

Predicine Holdings Ltd

HAYWARD · Biotechnology

Diligence memoA one-page analyst read on Predicine Holdings Ltd — recommendation, valuation, rhythm, risks.
$26.2M
Total raised · real
3
Rounds
1.5×
Latest step-up
Top 29%
Sector rank · raised
Series A
Latest stage · inferred · Mon May 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Predicine Holdings Ltd looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.54× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.1 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Predicine Holdings Ltd behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
9.1 yr record
Peak capital year was 2020 with $12.7M across 1 filings.
Market position
ahead of 72% of Biotechnology peers
Capital scale is ahead of 72% of Biotechnology peers; modeled value is above 82% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2020: $12.7M across 1 filings.
  • Largest single filing was $12.7M on 2020-05-18.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Predicine Holdings Ltd is one of 4293 Biotechnology companies tracked from HAYWARD. By capital raised it ranks in the upper tier (ahead of 72% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2015
Year incorporated
2020-05-18
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2017-05-31 Raised $5.0M (real) Modeled valuation $181M (est)$5.0M$181MSeries A2017Series A · 2018-02-05 Raised $8.5M (real) Modeled valuation $308M (est)$8.5M$308MSeries A2018Series A · 2020-05-18 Raised $13M (real) Modeled valuation $459M (est)$13M$459MSeries A2020+$8.5M+$13MCumulative $26M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.0M · 2017
Series A extension$8.5M · 2018
Series A extension$12.7M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$458.6M
Base estimate est.
$13.8M
Conservative case
$2.5B
Upside case
$57.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $180.8M · 2017-05-312017Series A · modeled $308.2M · 2018-02-05Series A · modeled $458.6M · 2020-05-182020
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
6.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
18 mo
Avg between rounds
$8.8M/yr
Capital velocity
9.1 yr
On record since
2017
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.6× above median
This company$26.2M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.3× above median
This company$12.7M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 7.1× above median
This company$458.6M
Sector median$64.2M

Raised more than 72% of sector peers (real $). Modeled value above 82% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #13 of 216.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $485.3M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)Predicine Holdings Ltd (this company) Raised $26.2M · modeled $458.6M (est)Predicine Holdings Ltd
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Taiga Biotechnologies, Inc.Series A$37.9M$485.3M2.68×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
Predicine Holdings Ltd this companySeries A$26.2M$458.6M2.54×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.0M2017-05-31$22.7M$180.8M90%
Series A$8.5M2018-02-05$38.8M$308.2M90%
Series A$12.7M2020-05-18$57.7M$458.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.0M2017-05-31
    • First recorded raise — entered as Series A.
    • 4 investors on this round.
  2. Series A$8.5M2018-02-05
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 4 investors on this round.
  3. Series A$12.7M2020-05-18
    • Raised again after 27 mo — slower than the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • 6 investors on this round.
Intelligence
2021 ~Q4
Modeled next raise · ~18mo cadence
$18.9M
Modeled next size est.range $12.7M$30.2M
1.5×
Last step-up
$8.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Haipeng Cheng1 other2017-05
Qian Wang1 other2017-05
N/A CIA Asia Corporate Services Limited Of Start Chambers2017-05
Pan Du2017-05
Shidong Jia2017-05
Yuexing Su2020-05
Registry & provenance

Predicine Holdings Ltd is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1806237
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Akebia Therapeutics, Inc.BiotechnologySeries A$25.9M$504.1Msame sector · same stage
IntraVu, Inc.BiotechnologySeries A$26.5M$320.5Msame sector · same stage
Agilis Biotherapeutics, Inc.BiotechnologySeries A$25.7M$458.0Msame sector · same stage
Molecular Biometrics IncBiotechnologySeries A$25.3M$461.1Msame sector · same stage
Velomedix, Inc.BiotechnologySeries A$27.3M$335.9Msame sector · same stage
Elevation Pharmaceuticals IncBiotechnologySeries A$27.4M$448.3Msame sector · same stage
ALDEA Pharmaceuticals, Inc.BiotechnologySeries A$27.5M$334.9Msame sector · same stage
Aldeyra Therapeutics, Inc.BiotechnologySeries A$24.6M$361.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Precipio, Inc.BiotechnologySeries B$32.2M88%
Precidiag, Inc.BiotechnologySeed$39.6M87%
Next Science LtdBiotechnologyPre-Seed$6.3M85%
NeXtGen Biologics, INCBiotechnologySeed$347K85%
Safeguard Biosystems Holdings LtdBiotechnologySeed$155.4M85%
Prana Biosciences Inc.BiotechnologyPre-Seed$757K84%
Novita Pharmaceuticals, Inc.BiotechnologySeries A$86.4M83%
Evergaze Holdings LLCBiotechnologySeries B$793.8M83%
Frequently asked
How much funding has Predicine Holdings Ltd raised?
Predicine Holdings Ltd has raised approximately $26.2M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Predicine Holdings Ltd's estimated valuation?
Provath's modeled valuation for Predicine Holdings Ltd is approximately $458.6M (modeled range $13.8M–$2.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Predicine Holdings Ltd at?
Predicine Holdings Ltd's latest modeled financing stage is Series A. Its most recent recorded round closed around Mon May 18.
What does Predicine Holdings Ltd do and where is it based?
Predicine Holdings Ltd operates in the Biotechnology sector, based in HAYWARD.
Explore related

See where Predicine Holdings Ltd sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Predicine Holdings Ltd, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.